Search Results - "Delayen, Aurélie"
-
1
Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment
Published in Joint, bone, spine : revue du rhumatisme (01-05-2016)“…Abstract Objective To investigate the cutaneous tolerance of febuxostat in gouty patients with skin intolerance to allopurinol. Methods We identified all gouty…”
Get full text
Journal Article -
2
Synthesis and biological evaluation of a new family of anti-benzylanilinosulfonamides as CA IX inhibitors
Published in European journal of medicinal chemistry (01-02-2009)“…We report the synthesis and the pharmacological evaluation of a new class of human carbonic anhydrase (hCA) inhibitors prepared regio- and stereoselectively by…”
Get full text
Journal Article -
3
A Convenient New Synthesis of 1,2-Diarylpyrroles from 3-Ethoxycarbonyl-4-oxo-4-phenylbutyraldehyde
Published in Heterocycles (01-07-2005)Get full text
Journal Article -
4
(2RS,5SR,6SR)-Methyl 4-{cis-2-[3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxymethyl]-6-hydroxy-3-phenylmorpholino}benzenesulfinate
Published in Acta crystallographica. Section C, Crystal structure communications (01-02-2006)“…The title compound, C30H34FNO7S, is a key intermediate in the design of dual 5‐LOX (5‐lipoxygenase)/COX‐2 (cyclooxygenase‐2) inhibitors. The compound…”
Get full text
Journal Article -
5
(2RS,5SR,6SR)-Methyl 4-{cis-2-[3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxymethyl]-6-hydroxy-3-phenylmorpholino}-benzenesulfinate
Published in Acta crystallographica. Section C, Crystal structure communications (01-02-2006)“…The title compound, C30H34FNO7S, is a key intermediate in the design of dual 5-LOX (5-lipoxygenase)/COX-2 (cyclooxygenase-2) inhibitors. The compound…”
Get full text
Journal Article